A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T

Multiple sclerosis (Houndmills, Basingstoke, England)1 Feb 2002Cited by 62 (Europe PMC)

PMID11936485DOI10.1191/1352458502ms768oaPepBankPUB-11936485

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, contrast enhancing lesion frequency did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, active lesion frequency did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeContrast enhancing lesion frequency
Study
n = 7
Comparator
Baseline period
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome measure was contrast enhancing lesion (CEL) frequency on treatment compared to baseline.
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648501
02HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, white matter lesion load did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, white matter lesion load did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeWhite matter lesion load
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regi…
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648502
03HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, magnetization transfer ratio did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, this MRI measure did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeMagnetization transfer ratio
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regi…
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648503
04HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, T1-Hypointensity volume did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, this lesion volume did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeT1-Hypointensity volume
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regi…
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648504
05HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, cervical spine cross-sectional area did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, cervical spine area did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeCervical spine cross-sectional area
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regi…
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648505
06HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, regional metabolite ratios did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, metabolite ratios did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeRegional metabolite ratios
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary outcome measures included dinical and MRI measures of disease activity including: white matter lesion load (WMLL), magnetization transfer ratio (MTR), T1-Hypointensity volume, cervical spine cross-sectional area and proton magnetic resonance spectroscopic (MRS) imaging for determining regi…
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648506
07HumanNon-randomized trialEfficacy outcome
In multiple sclerosis patients, clinical disease activity did not differ between rhIGF-1 treatment and baseline periods.
In plain wordsIn multiple sclerosis patients, clinical disease activity did not differ between rhIGF-1 treatment and baseline periods.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeClinical disease activity
Study
n = 7
Comparator
Baseline period
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no significant difference between baseline and treatment periods for any MRI or clinical measures of disease activity.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648507
08HumanNon-randomized trialSafety outcome
In multiple sclerosis patients, rhIGF-1 was well tolerated with no severe adverse reactions.
In plain wordsIn multiple sclerosis patients, rhIGF-1 was well tolerated with no severe adverse reactions.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableSevere adverse reactions
Study
n = 7
Outcome group
Adverse events · Whole body
Studied dose
50 mg twice a day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
rhIGF-1 was safe and well tolerated with no severe adverse reactions.
2 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this open-label, crossover study was to determine the safety and efficacy of recombinant insulin-like growth factor-1 (rhIGF-1) using magnetic resonance imaging (MRI) and clinical measures of disease activity in seven multiple sderosis (MS) patients.
Summary · context
Monthly clinical and MPI examinations were performed during a 24-week baseline and a 24-week treatment period with rhIGF-1.
Report a problemFND-1193648508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.